Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Trial to Assess Safety, Tolerability and Anti-tumor Activity of Autologous T Cell Modified Chimeric Antigen Receptor (CAR) (CCT303-406) in Patients With Relapsed or Refractory HER2 Positive Solid Tumors

NCT04511871 is registered in ClinicalTrials.gov with Shanghai PerHum Therapeutics Co., Ltd. as lead sponsor.

NCT NCT04511871
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04511871 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Trial to Assess Safety, Tolerability and Anti-tumor Activity of Autologous T Cell Modified Chimeric Antigen Receptor (CAR) (CCT303-406) in Patients With Relapsed or Refractory HER2 Positive Solid Tumors
Lead sponsor
Shanghai PerHum Therapeutics Co., Ltd.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
July 9, 2020
Completion date
March 29, 2025
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, gastric cancer, ovarian cancer, sarcoma, solid tumor